QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: How National Marketing Authorisation Procedures Work in the EU

Test your understanding of the concepts covered by How National Marketing Authorisation Procedures Work in the EU.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A CMS raises a concern during an MRP or DCP that prevents agreement on the assessment or benefit-risk balance. What is the most appropriate general interpretation?

The RMS assessment is automatically binding and no further mechanism exists The concern may trigger an applicable formal EU-level disagreement or referral procedure, depending on the legal conditions The product automatically receives a centralised authorisation The CMS must grant the national authorisation without recording the concern

Question 2 of 10 For a QPPV overseeing a portfolio containing nationally authorised medicines, which approach is most appropriate?

Track only the Union institution because national authorities are not relevant to pharmacovigilance Record the authorisation status, participating Member States, relevant authorities, procedural history and potential Union procedures Treat all nationally authorised products as if they had identical regulatory interfaces Focus exclusively on the original marketing authorisation application and ignore later procedures

Question 3 of 10 Which statement best describes the pharmacovigilance implications of national authorisation?

Nationally authorised medicines are outside the EU pharmacovigilance framework Only centrally authorised products require a functioning pharmacovigilance system Nationally authorised medicines remain subject to the EU pharmacovigilance framework and may contribute to Union-level safety assessment Pharmacovigilance responsibility transfers entirely from the marketing authorisation holder to the NCA

Question 4 of 10 Which set of questions provides the most useful starting point for reconstructing a product's regulatory history?

What is the product's sales volume, promotional budget, and preferred distributor? What type of authorisation exists, who granted it, where does it have legal effect, and which procedure created it? Which safety signal was identified first, and which department owns the product? Was the product developed inside or outside the EU, and is it commercially successful?

Question 5 of 10 What is the defining starting condition for a decentralised procedure?

The product already has a national authorisation in the RMS The product already has a centralised Union authorisation The applicant seeks authorisation simultaneously in participating Member States where the relevant national authorisation does not yet exist The product is being converted from a national authorisation into a Union authorisation

Question 6 of 10 What is the defining starting condition for a mutual recognition procedure?

No participating Member State has any relevant national authorisation An existing national marketing authorisation is available to form the basis for recognition A centralised marketing authorisation has already been granted The product must already be authorised in every Member State

Question 7 of 10 Which statement best explains why a national competent authority is not operating outside the European medicines regulatory system?

National authorities may disregard EU requirements when applying national law National authorities apply the common EU framework and participate in the European regulatory network National authorities only regulate products that are exempt from EU pharmaceutical legislation National authorities act as delegated offices of the European Commission

Question 8 of 10 Which statement best captures the relationship between national authorities and Union coordination mechanisms?

National authorities must choose between exercising national powers and participating in Union mechanisms National authorities can grant or maintain national authorisations while also contributing to EU committees, procedures, inspections and pharmacovigilance National authorities participate in Union mechanisms only after transferring all national authorisations to EMA Union coordination eliminates the need for national competent authorities

Question 9 of 10 Which feature most fundamentally distinguishes a national marketing authorisation from a centralised marketing authorisation?

The scientific standards applied to the product The legal authority and procedure through which the authorisation is granted Whether pharmacovigilance obligations apply after authorisation Whether the product must have clinical evidence

Question 10 of 10 What is the legal nature of the authorisations resulting from a successful MRP or DCP?

A single Union marketing authorisation National marketing authorisations in the participating Member States Temporary scientific opinions without legal effect Authorisations issued directly by the RMS on behalf of the European Commission

Knowledge Assessment: How National Marketing Authorisation Procedures Work in the EU

Cookie Settings